RVX at this point needs much much more analyst coverage than Beacon, will this be the start of analyst coverage from  many other investment firms small and large. That type of coverage could help the sp, The only thing that occurred to me is what is the advantage  for an investment firms coverage if they are not involved in an financing or IPO, 

maybe they see RVX as a good buying opportunity for their clients who invest in speculative biotech investments. I doubt that would be the case. I would love to see it but doubt in the short term

If however we get FA pass then maybe a major news outlet would report an article and may want to pick up this type of  important news . That is what I think we need to move the SP up a lot.

RVX need a communications director or firm helping market or promote the company to larger investment community as very people know RVX exists. That is more likely the best scenario. I remember about 6 or 7 years and article on RVX came out in Forbes magazine prior to the Assure trial and the stock up quite a bit for a while after. Hopefully we have found a bottom and that we start getting much more coverage in every way,